The efficacy of therapy with DPP-4 inhibitors combined with insulin in patients with type 2 diabetes mellitus

Recently, researchers started to pay increasingly more attention to the role of gastrointestinal hormones in regulation of insulin secretion, i.e. glucosehomeostasis. To-day, there are two approaches to the treatment of DM based on the use of GLP-1 effects. One takes advantage of DPP-4 inhibitorsthe...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Alexander Sergeevich Ametov, Ekaterina Vladimirovna Karpova
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2011
Materias:	diabetes mellitus vildagliptin combination therapy Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/50ccb5d0d00840d48e019f9b30b4e594
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:50ccb5d0d00840d48e019f9b30b4e594
record_format	dspace
spelling	oai:doaj.org-article:50ccb5d0d00840d48e019f9b30b4e5942021-11-14T09:00:16ZThe efficacy of therapy with DPP-4 inhibitors combined with insulin in patients with type 2 diabetes mellitus2072-03512072-037810.14341/2072-0351-5818https://doaj.org/article/50ccb5d0d00840d48e019f9b30b4e5942011-12-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/5818https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Recently, researchers started to pay increasingly more attention to the role of gastrointestinal hormones in regulation of insulin secretion, i.e. glucosehomeostasis. To-day, there are two approaches to the treatment of DM based on the use of GLP-1 effects. One takes advantage of DPP-4 inhibitorsthe other is combination of these agents with various drugs necessitated by heterogeneity of pathophysiological factors responsible for the developmentof DM2. The latter approach ensures multiple therapeutic effects on DM2 and its complications. Many on-going studies are focused on the use ofcombination of DPP-4 inhibitors and insulin. Vildagliptin (Galvus, Novartis Pharma, Switzerland) is presently the sole DPP-4 inhibitor approvedfor application with insulin in Russia.Aim. To estimate the efficacy and safety of DPP-4 inhibitor combined with long-acting insulin in the treatment of DM2. Materials and methods. The study group included 18 patients (2 men and 16 women) with DM2 treated with long-acting insulin (glargine, humulinNPH) for at least 3 months at a mean daily dose of 31.96?4.95 U. The age of the patients averaged 59.9?2.84 years (46-75), DM2 duration8.9?1.18 years (2-15). Parameters of comprehensive glycemic control (FG, PPG, HbA1c, LMWH - low-molecular weight heparins CGM-continuousglucose monitoring) were measured using a CGMS system in the beginning and end of the study. Functional activity of pancreatic betbeta-cells and insulinresistance (HOMA-IR), lipid metabolism, and anthropometric characteristics were estimated. Results. Combined therapy resulted in positive dynamics of carbohydrate metabolism within 12 weeks after onset. The functional activity of pancreaticbetbeta-cells significantly (by 157.96 U) improved by the end of the study. Changes of HOMA-IR were insignificant. CGM showed that prescription ofvildagliptin to the patients who failed to reach compensation of DM2 with long-acting insulin alone significantly improved glycemic control. Variabilityof glycemia remained unaltered during the entire period. Conclusion. Combined therapy of DM2 patients with vildagliptin and long-acting insulin for 12 weeks improved parameters of carbohydrate metabolismwithout hypoglycemic episodes changes, in fluctuation amplitude and body weight. The functional activity of pancreatic betbeta-cells was likewiseimproved.Alexander Sergeevich AmetovEkaterina Vladimirovna KarpovaEndocrinology Research Centrearticlediabetes mellitusvildagliptincombination therapyNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 14, Iss 4, Pp 55-59 (2011)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	diabetes mellitus vildagliptin combination therapy Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	diabetes mellitus vildagliptin combination therapy Nutritional diseases. Deficiency diseases RC620-627 Alexander Sergeevich Ametov Ekaterina Vladimirovna Karpova The efficacy of therapy with DPP-4 inhibitors combined with insulin in patients with type 2 diabetes mellitus
description	Recently, researchers started to pay increasingly more attention to the role of gastrointestinal hormones in regulation of insulin secretion, i.e. glucosehomeostasis. To-day, there are two approaches to the treatment of DM based on the use of GLP-1 effects. One takes advantage of DPP-4 inhibitorsthe other is combination of these agents with various drugs necessitated by heterogeneity of pathophysiological factors responsible for the developmentof DM2. The latter approach ensures multiple therapeutic effects on DM2 and its complications. Many on-going studies are focused on the use ofcombination of DPP-4 inhibitors and insulin. Vildagliptin (Galvus, Novartis Pharma, Switzerland) is presently the sole DPP-4 inhibitor approvedfor application with insulin in Russia.Aim. To estimate the efficacy and safety of DPP-4 inhibitor combined with long-acting insulin in the treatment of DM2. Materials and methods. The study group included 18 patients (2 men and 16 women) with DM2 treated with long-acting insulin (glargine, humulinNPH) for at least 3 months at a mean daily dose of 31.96?4.95 U. The age of the patients averaged 59.9?2.84 years (46-75), DM2 duration8.9?1.18 years (2-15). Parameters of comprehensive glycemic control (FG, PPG, HbA1c, LMWH - low-molecular weight heparins CGM-continuousglucose monitoring) were measured using a CGMS system in the beginning and end of the study. Functional activity of pancreatic betbeta-cells and insulinresistance (HOMA-IR), lipid metabolism, and anthropometric characteristics were estimated. Results. Combined therapy resulted in positive dynamics of carbohydrate metabolism within 12 weeks after onset. The functional activity of pancreaticbetbeta-cells significantly (by 157.96 U) improved by the end of the study. Changes of HOMA-IR were insignificant. CGM showed that prescription ofvildagliptin to the patients who failed to reach compensation of DM2 with long-acting insulin alone significantly improved glycemic control. Variabilityof glycemia remained unaltered during the entire period. Conclusion. Combined therapy of DM2 patients with vildagliptin and long-acting insulin for 12 weeks improved parameters of carbohydrate metabolismwithout hypoglycemic episodes changes, in fluctuation amplitude and body weight. The functional activity of pancreatic betbeta-cells was likewiseimproved.
format	article
author	Alexander Sergeevich Ametov Ekaterina Vladimirovna Karpova
author_facet	Alexander Sergeevich Ametov Ekaterina Vladimirovna Karpova
author_sort	Alexander Sergeevich Ametov
title	The efficacy of therapy with DPP-4 inhibitors combined with insulin in patients with type 2 diabetes mellitus
title_short	The efficacy of therapy with DPP-4 inhibitors combined with insulin in patients with type 2 diabetes mellitus
title_full	The efficacy of therapy with DPP-4 inhibitors combined with insulin in patients with type 2 diabetes mellitus
title_fullStr	The efficacy of therapy with DPP-4 inhibitors combined with insulin in patients with type 2 diabetes mellitus
title_full_unstemmed	The efficacy of therapy with DPP-4 inhibitors combined with insulin in patients with type 2 diabetes mellitus
title_sort	efficacy of therapy with dpp-4 inhibitors combined with insulin in patients with type 2 diabetes mellitus
publisher	Endocrinology Research Centre
publishDate	2011
url	https://doaj.org/article/50ccb5d0d00840d48e019f9b30b4e594
work_keys_str_mv	AT alexandersergeevichametov theefficacyoftherapywithdpp4inhibitorscombinedwithinsulininpatientswithtype2diabetesmellitus AT ekaterinavladimirovnakarpova theefficacyoftherapywithdpp4inhibitorscombinedwithinsulininpatientswithtype2diabetesmellitus AT alexandersergeevichametov efficacyoftherapywithdpp4inhibitorscombinedwithinsulininpatientswithtype2diabetesmellitus AT ekaterinavladimirovnakarpova efficacyoftherapywithdpp4inhibitorscombinedwithinsulininpatientswithtype2diabetesmellitus
_version_	1718429580597919744

The efficacy of therapy with DPP-4 inhibitors combined with insulin in patients with type 2 diabetes mellitus

Ejemplares similares